Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.45 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL2392959 | 1.00 | LMNA (0.45) | LMNAALDH1A1KDM4ECYP3A4TSHR | |
| Fumaric Acid SCHEMBL2397990 | 1.00 | LMNA (0.45) | LMNAALDH1A1KDM4ECYP3A4TSHR | |
| Fumaric Acid SCHEMBL2398630 | 1.00 | LMNA (0.45) | LMNAALDH1A1KDM4ECYP3A4TSHR | |
| Fumaric Acid SCHEMBL2398624 | 1.00 | LMNA (0.45) | LMNAALDH1A1KDM4ECYP3A4TSHR | |
| Fumaric Acid SCHEMBL2392951 | 1.00 | LMNA (0.45) | LMNAALDH1A1KDM4ECYP3A4TSHR | |
| SCHEMBL2394588 | 0.88 | GRIN2D (0.46) | LMNAKDM4ECYP3A4TSHRMEN1 | |
| SCHEMBL2396116 | 0.88 | GRIN2D (0.46) | LMNAKDM4ECYP3A4TSHRMEN1 | |
| SCHEMBL2395871 | 0.88 | GRIN2D (0.46) | LMNAKDM4ECYP3A4TSHRMEN1 | |
| Fumaric Acid SCHEMBL2392534 | 0.88 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4ECYP3A4TSHR | |
| Fumaric Acid SCHEMBL2392541 | 0.88 | ALDH1A1 (0.39) | LMNAALDH1A1KDM4ECYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | claimed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | claimed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | claimed |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | BALESTRA MICHAEL (US) | 2012-05-10 | — | — | US | claimed |
| EP-2391606-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | claimed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | claimed |
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | ASTRAZENECA AB (SE) | 2012-11-01 | — | — | US | disclosed |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | BALESTRA MICHAEL (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2391606-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, HTR5A, TPH2 | MEN1 1584/4885KMT2A 295/4885KCNH2 509/4885 |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, TPH1, TPH2 | MEN1 658/4885KMT2A 143/4885KCNH2 283/4885 |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | TPH1, TPH2, PNMT | MEN1 1656/4885KMT2A 348/4885KCNH2 207/4885 |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | HTR5A, PNMT, GRIK5 | MEN1 1880/4885KMT2A 460/4885KCNH2 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.